5:58 PM
 | 
Mar 03, 2014
 |  BC Extra  |  Clinical News

Atopix reports mixed Phase II asthma data

One dose of OC459 from Atopix Therapeutics Ltd. (London, U.K.) met the primary endpoint while two other doses missed in a Phase IIb trial to treat mild to moderate persistent asthma. In the trial, 25 mg once-daily oral OC459 met the primary endpoint of significantly increasing mean percent predicted force expiratory...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >